eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
5/2010
vol. 48
 
Share:
Share:
more
 
 
abstract:
Editorial

Disease-modifying drugs – molecular and clinical aspects

Stefan Mackiewicz

Reumatologia 2010; 48, 5: 289–292
Online publish date: 2010/11/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Disease-modifying antirheumatic drugs (DMARDs) are involved in the control of inflammation. A great number of mechanisms take part in the treatment procedures undertaken in rheumatoid arthritis and allied conditions. Inhibition of biological hyperreactivity is the most important phenomenon operating in the signal transduction cascade (cells, genes, molecules), following DMARDs therapy. Clinical remission can be achieved in approximately 50% of treated patients.
keywords:

disease-modifying drugs, regulatory mechanism, signal transduction cascade (cells–genes–molecules)



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe